Please select the option that best describes you:
How do you manage stage III resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy per CheckMate 816 with residual disease who subsequently refuse surgery?
Would you recommend standard definitive chemoradiation followed by adjuvant durvalumab? Would you treat pre- or post-systemic therapy volumes?
Answer from: Radiation Oncologist at Community Practice
(1) Carefully analyze what happened with the patient, their medical oncologist, and thoracic surgeon, (2) restage the patient with an FDG-PET/CT and brain MRI to rule out distant metastatic progression, (3) confirm with their medical oncologist that CRT-> Durva is still an option, (4) confirm tha...
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
The PACIFIC trial was for unresectable patients, yet extrapolated to many resectable patients (one single station N2 node). If a patient is deemed resectable at tumor board, it’s by definition not eligible for PACIFIC. Thus, they may be treated with chemo-immunotherapy and then undergo surgery...
Comments
Medical Oncologist at Northwest Medical Specialties PLLC
If they responded to chemo IO, would probably do c...
If they responded to chemo IO, would probably do c...